Endpoints News

Epigenetic editing startup Moonwalk shifts focus to siRNA for obesity
表观遗传编辑初创公司Moonwalk将重心转向肥胖治疗用siRNA

Two years ago, CRISPR gene editing pioneer Feng Zhang and former Illumina chief technology officer Alex Aravanis launched a startup to develop medicines that would change how genes are turned on and off without altering DNA itself.
两年前,CRISPR基因编辑先驱张锋与前因美纳首席技术官亚历克斯·阿拉瓦尼斯创办了一家初创公司,致力于开发无需改变DNA本身即可调控基因开关的药物。

本报道最初发表于Endpoints News。请点击这里查看原文

Two years ago, CRISPR gene editing pioneer Feng Zhang and former Illumina chief technology officer Alex Aravanis launched a startup to develop medicines that would change how genes are turned on and off without altering DNA itself.

两年前,CRISPR基因编辑先驱张锋(Feng Zhang)与前因美纳(Illumina)首席技术官亚历克斯·阿拉瓦尼斯(Alex Aravanis)创办了一家初创公司,致力于开发无需改变DNA本身即可调控基因开关的药物。

您已阅读6%(374字),剩余94%(5552字)包含更多重要信息,订阅以继续探索完整内容,并享受更多专属服务。
版权声明:本文版权归Endpoints News所有,未经允许任何单位或个人不得转载,复制或以任何其他方式使用本文全部或部分,侵权必究。
设置字号×
最小
较小
默认
较大
最大
分享×